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Abstract
Tuberculosis is a major public health problem in Ethiopia. The aims of this study were (i) to
investigate the recovery rate of M. tuberculosis from smear positive single morning sputum specimens
subjected to long-term storage at -20°C, (ii) to assess the level and risk factors for first- and second-
line anti-TB drug resistance, (iii) to evaluate the performance of the GenoType®MTBDRplus and
GenoType®MTBDRsl assays for drug susceptibility testing compared to the BacT/ALERT 3D system
as reference method, (iv) to analyze the frequency of gene mutations associated with resistance to
isoniazid (INH), rifampicin (RMP) and ethambutol (EMB) among M. tuberculosis isolates, and (v) to
study the population structure and transmission dynamics of M. tuberculosis isolates from patients in
Amhara region, Northwest Ethiopia. The median specimen storage time was 132 days. Of 319
specimens, 90.0% were culture positive. The length of time of sputum storage had no significant effect
on the recovery rate of M. tuberculosis. Of 260 M. tuberculosis isolates, 15.8% were resistant to at
least one first-line drug, 5.0% were multidrug resistant (MDR) and 3.5% were resistant to all first-line
drugs. Any resistance to INH, RMP, streptomycin (STM), EMB and pyrazinamide (PZA) was 13.8%,
5.8%, 10.0%, 7.3% and 4.6%, respectively. All isolates were susceptible to second-line drugs. The
GenoType®MTBDRplus assay had a sensitivity of 92% and specificity of 99% to detect INH
resistance, and 100% sensitivity and specificity to detect RMP resistance and MDR. The
GenoType®MTBDRsl assay had a sensitivity of 42% and specificity of 100% to detect EMB
resistance. According to the molecular methods, mutations conferring resistance to INH, RMP, or
EMB were detected in 13.5%, 5.8%, and 3.1% of the isolates, respectively, while mutation conferring
MDR was present in 5.0% of the isolates. Of 244 M. tuberculosis isolates, 59.0% were classified as
known lineages; Dehli/CAS (38.9%), Haarlem (8.6%), Ural (3.3%), LAM (3.3%), TUR (2.0%), X-
type (1.2%), S-type (0.8%), Beijing (0.4%) and Uganda II (0.4%) lineage. Interestingly, 31.6% of the
isolates were grouped in to four previously undefined phylogenetic lineages and were named as
Ethiopia_3 (13.1%), Ethiopia_1 (7.8%), Ethiopia_H37Rv like (7.0%) and Ethiopia_2 (3.7%) lineages.
The remaining 9.4% of the isolates could not be assigned to the known or new lineages. Overall,
45.1% of the isolates were grouped in clusters, indicating high rate of recent transmission. Similarly,
66.7% of MDR strains were grouped in clusters.
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Introduction
Mycobacterium tuberculosis complex
The Mycobacterium tuberculosis complex (MTBC) comprised of closely related species including the
human pathogens; M. tuberculosis, M. africanum and M. canettii and the animal adapted species; M.
bovis (bovine), M. caprae (goats), M. pinnipedii (seals), and M. microti (rodents) (1-7). M.
tuberculosis is the predominant cause of human tuberculosis (TB) worldwide but M. africanum and M.
bovis remain important agents of human disease in certain geographical regions. Mycobacterium
tuberculosis is a rod-shaped, non-motile, non-spore-forming, aerobic bacterium, classified as acid-fast
bacilli, and has a unique cell wall structure crucial to its survival (8). The cell wall contains a
considerable amount of fatty acid, mycolic acid, covalently attached to the underlying peptidoglycan-
bound polysaccharide arabinogalactan, providing an extraordinary lipid barrier. This barrier is
responsible for many of the medically challenging physiological characteristics of M. tuberculosis,
including resistance to antibiotics and host defence mechanisms. The composition and quantity of the
cell wall components also affect the bacteria’s virulence and growth rate (9).
Transmission and pathogenesis of M. tuberculosis
Mycobacterium tuberculosis spread by small airborne droplets generated during coughing, sneezing,
talking, or singing of a person with pulmonary or laryngeal tuberculosis. The droplets are small
enough in size (1-5 µm in diameter) to allow passage into the lower respiratory tract and can remain
suspended in the air for several minutes to hours (10, 11). Droplets of a larger size are efficiently
excluded from the lower respiratory tract by the physical barriers of the nasopharynx and upper
respiratory tract (12). The transmission of M. tuberculosis from a TB patient to a contact person
depends on (i) exposure duration; (ii) intensity of exposure; (iii) cough and sputum-related host
factors; and (iv) M. tuberculosis strain-related virulence characteristics (13). The most important
source of M. tuberculosis infection is a person with smear-positive pulmonary tuberculosis (14, 15).
Phases of M. tuberculosis infection and pathogenesis have been described previously (16-18). As
shown in Figure 1, the first stage begins with inhalation of the tubercle bacilli. Once the bacilli have
made their way into the lung, the bacilli are engulfed by alveolar phagocytic cells (macrophages and
dendritic cells) and often destroyed. Tubercle bacilli which escape the initial intracellular destruction
will replicate intracellularly, and the bacteria-laden phagocytic cells may cross the alveolar barrier to
cause systemic dissemination. The intracellular replication and simultaneous dissemination of the
pathogen to the pulmonary lymph nodes and to various other extrapulmonary sites occur prior to the
development of the adaptive immune responses. In the vast majority of the infected individuals, an
effective cell-mediated immune response develops 2–8 weeks after infection that stops further
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multiplication of the tubercle bacilli. The activated T lymphocytes, macrophages, and other immune
cells form granulomas that wall off the growing necrotic tissue limiting further replication and spread
of the tubercle bacilli. Most of the bacilli are killed in the granulomas, and disease progression is
arrested. However, the bacilli are not completely eradicated in some individuals as M. tuberculosis
escape killing by blunting the microbicidal mechanisms of phagocytic cells (such as phagosome-
lysosome fusion, production of nitric oxide, and other reactive nitrogen intermediates). As a result, 5-
10% of cases develop active disease (primary tuberculosis), while in the majority (90-95%) of cases
the bacilli remain in a non-replicating (dormant/latent) state (latent tuberculosis infection), which is
probably reflected by the M. tuberculosis DNA that can be detected using in situ PCR (shown in
Figure 1 as blue intracytoplasmic material) in tissue. A subsequent defect in cell-mediated immunity
may result in reactivation of dormant bacilli causing active disease many years after the infection
(reactivation TB). Only approximately 10% of individuals with latent tuberculosis infection will
develop the disease at some point of their life. For persons co-infected with HIV this risk increases to
approximately 10% annually (19, 20). Progressive disease is characterized by weight loss, cavitations
and fibrosis. Some of the cavities eventually open into the bronchi, which allow the bacilli to spread
through the airways to other parts of the lung and the outside environment during coughing.
Figure 1. Phases of infection with Mycobacterium tuberculosis (18).
~10% in life time, ~10% annually for HIV+
Latent TB
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The global burden of tuberculosis
Tuberculosis remains one of the major public health problems worldwide. In 2009, WHO estimated
9.4 million incident cases of TB globally (equivalent to 137 per 100,000 population). The prevalence
rate was estimated to be 200 per 100,000 population, which is equivalent to 14 million TB cases. The
absolute number of cases continues to increase slightly from year to year, as slow reductions in
incidence rates per capita continue to be outweighed by increases in population. Most of the estimated
number of cases in 2009 occurred in Asia (55%) and Africa (30%). Smaller proportions of cases
occurred in the Eastern Mediterranean region (7%), the European region (4%) and the region of the
Americas (3%). The 22 high burden tuberculosis countries account for 81% of all estimated cases
worldwide (21). Of the 9.4 million incident cases in 2009, an estimated 1.1 million (12%) were HIV-
positive. Of which, approximately 80% were in the African region. Approximately 1.7 million people
died of TB in 2009. Of which, 1.3 million deaths occurred among HIV-negative TB cases and 0.4
million deaths were among HIV-positive TB cases (21).
Tuberculosis in Ethiopia
According to the population census in 2007, Ethiopia has a total population of about 74 million. The
second largest proportion of the country’s population is found in the Amhara region (23.3%), which is located
in Northwest part of Ethiopia (22). According to the WHO’s global TB report, Ethiopia ranks seventh
among the world’s 22 high-burden tuberculosis countries. The country had 314,267 TB cases in 2007,
with an estimated incidence rate of 378 cases per 100,000 populations (23). The Ministry of Health
hospital statistics data also showed that tuberculosis is one of the leading causes of morbidity, the
fourth most common cause of hospital admission, and the second most common cause of hospital
death in Ethiopia. TB mortality rate is estimated at 84 per 100,000 populations per year.  The high
prevalence of HIV infection, widespread poverty and overcrowding has created an environment which
made tuberculosis a formidable threat in Ethiopia (24). The epidemiological analysis of tuberculosis in
Ethiopia for the period of 2000-2007 has shown that the total number of new TB cases per year has
increased from 83,334 to 126,809. An increasing trend was observed for smear positive TB cases from
26,459 to 38,040, smear negative TB cases from 30,333 to 43,500 and extrapulmonary TB cases from
26,542 to 45,269 during the eight years period (Fig. 2) (25). Similarly, another epidemiological study
from 2000 to 2009 showed that the total number of new TB cases is generally increasing in Oromiya,
Amhara and SNNP regions (26).
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Figure 2. Notified cases of TB in Ethiopia in the last eight years (25).
           EPTB=Extrapulmonary tuberculosis
Our previous report from Gondar, Northwest Ethiopia has shown that tuberculosis type among patients
visited Gondar hospital between 2003 and 2008 was categorized as extrapulmonary in 1133 (28.3%)
of cases, smear negative pulmonary tuberculosis in 2196 (54.9%) and smear positive pulmonary
tuberculosis in 671 (16.8%) of cases. During the study period, high proportion of patients died (10.1%)
or defaulted (18.3%) in the course of treatment (27).
The situation of HIV/AIDS in the Amhara region is one of the worst in the country. The prevalence
was estimated at 2.8% in 2009 and 2.9% in 2010 in the region, which is higher than the prevalence of
HIV/AIDS in the country estimated at 2.3% in 2009 and 2.4 in 2010 (28). In a previous study, TB-
HIV co-infection rate, 52.1% was reported from Gondar hospital (29). Our previous study at Gondar
hospital has also shown that the prevalence of HIV among blood donors was 3.5%. However,
significantly declining trends of HIV prevalence was observed over the five years study period (2003-
2007) (30). Moreover, our previous report from Gondar and Felege Hiwot hospitals showed
encouraging levels of non-adherence (17.3%) and non-readiness (13.9%) of patients living with
HIV/AIDS to highly active antiretroviral therapy (31).
Molecular Epidemiology of M. tuberculosis
Members of the MTBC are considered genetically monomorphic with a high level of genomic
sequence similarity (> 99.95%), limited horizontal gene transfer, and a clonal population structure (32,
33). This apparent homogeneity led to the assumption that genetic diversity among MTBC strains
would not be of clinical significance. However, recent data based on molecular genotyping methods
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such as MIRU-VNTR (mycobacterial interspersed repetitive unit - variable number tandem repeat)
typing, IS6110 RFLP and spoligotyping revealed a highly diverse population structure of M.
tuberculosis with at least five major geographically-associated lineages including African (Uganda,
Cameroon and S-type), Asian (Beijing and CAS), Latin American-Mediterranean (LAM), African-
European populations (X-type, Ghana and Haarlem) and East African- Indian (EAI) lineages that can
also be further subdivided into well-defined genotypes (34, 35).
Molecular epidemiological investigations have contributed significantly to the understanding of the
epidemiology and control of tuberculosis by providing information on transmission dynamics (36),
determining the importance of reactivation versus exogenous reinfection (37),
investigating/confirming outbreaks (38), confirmation of laboratory cross contamination (39) and to
identify the clonal spread of successful clones, including multi-drug-resistant ones (40). In addition,
molecular markers can be used to evaluate host- and strain-specific risk factors and possible genotype-
specific differences in phenotypes such as virulence and transmissibility (41-43).
Anti-tuberculosis drugs and mechanisms of drug resistance in M. tuberculosis
Anti-tuberculosis drugs used for the treatment of TB are classified as first and second line drugs. First
line drugs include ethambutol (EMB), isoniazid (INH), pyrazinamide (PZA), rifampicin (RMP) and
streptomycin (STM). STM is no longer considered as a first line drug by ATS/IDSA/CDC because of
high rates of resistance. Second line drugs include six classes of drugs: aminoglycosides e.g., amikacin
(AMK) and kanamycin (KM); polypeptides e.g., capreomycin (CPM), viomycin and enviomycin;
fluoroquinolones e.g., ciprofloxacin (CIP), levofloxacin (LFX), ofloxacin (OFX) and moxifloxacin
(MXF); thioamides e.g. ethionamide (ETO) and prothionamide; cycloserine (CS); and p-
aminosalicylic acid (PAS).  A drug may be classified as second-line instead of first-line for one of
three possible reasons: it may be less effective than the first-line drugs; or, it may have higher toxic
side-effects; or it may be unavailable in many developing countries (44).
According to a recently published review on the mechanisms of drug resistance in M. tuberculosis
(45), genetic resistance to anti-tuberculosis drug is due to spontaneous chromosomal mutations at a
frequency of 10-6 to 10-8 mycobacterial replications. Mobile genetic elements such as plasmids and
transposons, which are known to mediate drug resistance in various bacterial species, do not do so in
M. tuberculosis. Mutations resulting in drug resistance are unlinked, thus the probability of
developing bacillary resistance to three drugs used simultaneously is virtually non-existent.  However,
amplification of the afore-mentioned genetic mutation through human mistakes results in clinically
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drug resistant TB. Human mistakes include monotherapy due to irregular drug supply, inappropriate
prescription and, most importantly, poor patient compliance (46). Subsequent transmission of resistant
strains from the index patient to others aggravates the problem. Alternative mechanisms such as active
efflux pumping and decreased cell wall permeability to drugs are likely to be important for several
drugs especially in phenotypically resistant isolates in which no mutation is detected in the target
genes (47-52).
Table 1. Mechanisms of drug resistance in M. tuberculosis (45)
MIC=minimum inhibitory concentration; ACP=acyl carrier protein; PAS=para-aminosalicylic acid.
According to the WHO report, the overall proportion of multidrug resistant tuberculosis (MDR-TB)
was 5.3%, ranging from 0% to 35% of reported TB cases globally (53). The number of countries
reporting at least one case of extremely drug-resistant tuberculosis (XDR-TB) had risen to 58 by
January 2010, although this rise is probably a result of increased efforts to identify XDR tuberculosis
rather than an increase in prevalence or distribution of the disease (54).
Drug (year of
discovery)
MIC
μg/ml
Gene(s)
involved
in
resistance
Gene function Role Mechanism of
action
Mutation
frequency
%
katG Catalase-peroxidase Pro-drug
conversion
50–95Isoniazid (1952) 0.02–0.2
inhA Enoyl ACP reductase Drug target
Inhibition of
mycolic acid
biosynthesis and
other multiple
effects
8–43
Rifampicin (1966) 0.05–1 rpoB β subunit of RNA
polymerase
Drug target Inhibition of RNA
synthesis
95
Pyrazinamide
(1952)
16–50
(pH 5.5)
pncA Nicotinamidase/pyrazinam
idase
Pro-drug
conversion
Depletion of
membrane energy
72–97
Ethambutol (1961) 1–5 embB Arabinosyl transferase Drug target Inhibition of
arabinogalactan
synthesis
47–65
rpsL S12 ribosomal protein Drug target 52–59
rrs 16S rRNA Drug target 8–21
Streptomycin
(1944)
2–8
gidB rRNA methyltransferase
(G527 in 530 loop)
Drug target
Inhibition of
protein synthesis
?
Amikacin/kanamyc
in (1957)
2–4 rrs 16S rRNA Drug target Inhibition of
protein synthesis
76
Capreomycin
(1960)
tlyA 2’-O-methyltransferase
gyrA DNA gyrase subunit A Drug target 75–94Quinolones (1963) 0.5–2.5
gyrB DNA gyrase subunit B
Inhibition of DNA
gyrase
etaA/ethA Prodrug
conversion
37Ethionamide
(1956)
2.5–10
inhA
Flavin monooxygenase
Drug target
Inhibition of
mycolic acid
synthesis 56
PAS (1946) 1–8 thyA Thymidylate synthase Drug
activation?
Inhibition of folic
acid and iron
metabolism?
36
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Drug resistant TB in Ethiopia
In Ethiopia, there have been reports on drug resistance of TB, mainly from the capital city, Addis
Ababa. A report on anti-TB drug resistance, probably the first in the country among new TB patients
of Addis Ababa was reported in 1984, this report showed a drug resistance rate of 15% for isoniazid,
5% for streptomycin and 5% for both isoniazid and streptomycin. There was no rifampicin resistance
reported and hence no MDR TB (55). The first MDR TB prevalence among new cases was reported in
1986 to be 1% (56). In 1998, a study which included all health centres and hospitals of Addis Ababa
reported 0.6% MDR-TB prevalence (57). In 2001, a report from Addis Ababa showed the level of
MDR-TB was nearly 2.7% among new cases and 5.3% for new and re-treatment cases combined (58).
Later on, a study performed in 2003 on re-treatment patients of St. Peter’s hospital in Addis Ababa
showed 26% MDR (59).
The countrywide anti-TB drug resistance survey conducted in 2005 showed that the prevalence of
MDR-TB was 1.6% and 11.8% among new and previously treated TB cases, respectively (52).
Moreover, according to WHO report in 2008, about 5825 MDR-TB cases (4964 among newly
diagnosed and 861 among previously treated TB cases) were estimated to have occurred in 2006 in
Ethiopia (54). Consequently, the Ethiopian government has identified MDR-TB as one of priority
public health problem and started treatment program for MDR-TB patients. Treatment of MDR-TB
patients started in 2009 at St. Peter hospital, Addis Ababa and in 2010 at Gondar University hospital,
in the Amhara region. Since then, the number of patients on treatment has been increasing steadily, but
still only a fraction of the estimated Ethiopians with MDR-TB has access to the treatment (24). In
Ethiopia, the treatment regimens for category I and category II (retreatment regimen) tuberculosis
cases are 2 months (RMP-INH-EMB-PZA) plus 4 months (RMP-INH) and 2 months STM (RMP-
INH-EMB-PZA) plus 1 month (RMP-INH-EMB-PZA) plus 5 months (EMB3 (RMP-INH)3),
respectively (25). The standard treatment regimen for MDR-TB is 6 months (EMB-PZA-KM (AMK)–
LFX–ETO-CS) plus 12 months (EMB-PZA-LFX–ETO–CS) (24).
The rationale for the study
The objectives of a TB control program are to reduce morbidity, mortality, transmission of TB and
emergence of drug resistance. Well-planned TB control programs may lead to achieve these goals (60,
61). However, the TB control program in Ethiopia suffers from shortage of information necessary for
proper planning and evidence-based decision making. Therefore, this study was done to fill these
information gaps.
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Despite the high prevalence of tuberculosis in the country, culture and drug susceptibility testing of M.
tuberculosis is being done only in the national reference laboratory, in the capital city, Addis Ababa.
The successful isolation of M. tuberculosis from remote settings requires proper collection, storage
and transportation of sputum specimens to TB laboratories (62-64). To ensure high yield of positive
cultures, WHO recommends that two sputum specimens be collected from remote areas and
transported to reference laboratories without delay (63). There may be a substantial cost associated
with handling, transportation and processing of two sputum specimens from each patient. In addition,
sputum specimen preservatives such as 0.6% cetylpyridinium bromide (CPB) or 1% cetylpyridinium
chloride (CPC) are recommended when delay is unavoidable. CPC, the most commonly used
preservative for the storage and transport of sputum specimens keeps the tubercle bacilli viable only
for up to 8 days (65-68). Moreover, previous studies have shown the negative effect of CPC on
microscopic examination and culture, including: (i) significant reduction in the positivity of AFB with
Ziehl-Neelsen staining (69, 70) and (ii) inhibition of mycobacterial growth, when inoculated in culture
media like Middlebrook 7H9 and 7H10 (67) and  Bactec MGIT 960 system (71). A simple and
inexpensive method for sputum storage that preserves the viability of tubercle bacilli for long periods
will be useful for epidemiological and drug resistance studies from remote settings. Therefore, the
present study was undertaken to investigate the recovery rate of M. tuberculosis from smear positive
single morning sputum specimens subjected to long term storage at -200C without addition of
chemical preservatives (Publication I).
In most high-burden TB countries including Ethiopia, drug resistant TB is only diagnosed after
prolonged treatment with first-line TB drugs and clinical recognition that treatment has failed.
Treatment of drug-resistant TB with standard first-line drugs, instead of a regimen designed according
to the resistance pattern has several potential adverse consequences: patients remain on inadequate
treatment longer, increasing the risk of treatment failure or death; selection of drug resistant strains
and patients remain infectious, promoting transmission to close contacts (72). In order to optimize
standard anti-tuberculosis drug therapy and to increase the success of control programs, it is important
to know drug resistance pattern in a country (73). However, only limited data on drug resistant TB are
available in Ethiopia. Thus, there is a great need to study the extent of the drug resistant tuberculosis in
Ethiopia in order to develop effective control strategies. Therefore, this study aimed to assess the level
and risk factors for first and second-line drug resistance among new untreated and previously treated
smear positive tuberculosis patients in Northwest Ethiopia (Publication II).
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For proper treatment and control of tuberculosis, the WHO is recommending countries to expand their
capacity for culture based drug-susceptibility testing (DST) and consider new molecular-based assays
for diagnosing drug resistance (74, 75). Molecular methods of drug resistance testing, based on the
identification of gene mutations associated with drug resistance, like GeneXpert MTB/RIF assay, offer
an effective tool for determining drug resistance because of their high sensitivity, specificity and speed
(76). New molecular methods that have been developed to detect drug resistance include the
GenoType®MTBDRplus for detection of isoniazid and rifampicin resistance and the
GenoType®MTBDRsl for detection of resistance against ethambutol, fluoroquinolones (e.g. ofloxacin
and moxifloxacin), and aminoglycosides/cyclic peptides (e.g. capreomycin, viomicin/kanamycin and
amikacin) (Hain Lifescience, Nehren, Germany).
In Ethiopia, five regional laboratories are being rebuilt and equipped to perform culture and drug
susceptibility testing using methods including GenoType®MTBDRplus and GenoType®MTBDRsl
assays. The GenoType®MTBDRplus and GenoType®MTBDRsl assays have been studied in several
laboratories of other countries. However, there is a wide variation in circulating M. tuberculosis strains
worldwide (77, 78), and false negative results reported due to unique genetic mutations, affecting the
performance of molecular assays (79-85). Therefore, analysis of gene mutations associated with
resistance to anti-tuberculosis drugs and assessment of the performance of molecular methods for drug
resistance testing in different settings are needed to ensure acceptable performance of the assays. So
far, there was no report on the frequency of gene mutations associated with resistance to INH, RMP
and EMB and the applicability of these molecular assays for M. tuberculosis isolates from Ethiopia.
In this study, we evaluated the performance of the GenoType®MTBDRplus for detection of resistance
to INH, RMP and MDR and GenoType®MTBDRsl assay for detection of EMB resistance compared to
the automated, culture-based BacT/ALERT 3D system and analyzed the frequency of gene mutations
associated with resistance to INH, RMP and EMB among M. tuberculosis isolates from Amhara
region, Northwest Ethiopia (Publication III).
Recent advances in molecular technology such as mycobacterial interspersed repetitive unit-variable
number tandem repeat (MIRU-VNTR) 24-loci typing and spoligotyping methods provide a powerful
tool to analyze M. tuberculosis genotypes and transmission dynamics, which should be valuable for
development of effective tuberculosis control policy. In Ethiopia limited molecular epidemiological
studies have been done so far only for isolates from patients in the capital city, Addis Ababa (86-88).
These studies were limited by small sample size, incomplete epidemiological information and use of a
genotyping method with low strain discriminatory capacity. Based on IS6110 fingerprinting or
Introduction
10
spoligotyping, a variety of strains were not classifiable into phylogenetic lineages or clonal complexes
since the genotyping information was not informative due to homoplasy (89, 90). Therefore, the
presence of particular genotypes and clustering might simply be overlooked. Because these questions
have paramount scientific and public health importance, further studies addressing these questions
using more appropriate methods are urgently needed. The new genotyping technique based on MIRU-
VNTR 24-loci typing allows the simultaneous high-resolution discrimination of clinical isolates for
epidemiological studies and a valid phylogenetic strain classification (91). In this study, we investigate
the population structure and transmission dynamics of M. tuberculosis strains isolated from patients
living in Amhara region using MIRU-VNTR 24-loci and spoligotyping methods (Publication IV).
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Objectives
General objective
The overall aim of this study was to investigate a simple and inexpensive sputum storage method, to
document the patterns of drug resistance and gene mutations conferring resistance to anti-TB drugs, to
evaluate the performance of two molecular based drug susceptibility testing methods and to analyze
the population structure and transmission dynamics of Mycobacterium tuberculosis among HIV
positive and HIV negative tuberculosis patients in Amhara region, Northwest Ethiopia.
Specific objectives
1. To investigate the recovery rate of M. tuberculosis from smear positive single morning sputum
specimens subjected to long term storage at -200C without addition of chemical preservatives
(Publication I).
2. To assess the level and risk factors for first and second line anti-TB drug resistance among
new untreated and previously treated tuberculosis patients in Amhara region (Publication II).
3. To evaluate the performance of the GenoType®MTBDRplus for detection of resistance to INH,
RMP and MDR and GenoType®MTBDRsl assay for detection of EMB resistance among M.
tuberculosis isolates from patients in Amhara region compared to the BacT/ALERT 3D system
(Publication III).
4. To analyze the frequency of gene mutations associated with resistance to INH, RMP and EMB
among M. tuberculosis isolates from patients in Amhara region (Publication III).
5. To study the population structure and transmission dynamics of Mycobacterium tuberculosis
among tuberculosis patients living in Amhara region (Publication IV).
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Abstract
Background: Although Ethiopia ranks seventh among the world’s 22 high-burden tuberculosis (TB)
countries, little is known about strain diversity and transmission. In this study, we present the first in-
depth analysis of the population structure and transmission dynamics of M. tuberculosis strains from
Northwest Ethiopia.
Methods: 244 Mycobacterium tuberculosis complex (MTBC) isolates where analysed by MIRU-
VNTR (mycobacterial interspersed repetitive unit - variable number tandem repeat) 24-loci and
spoligotyping to determine phylogenetic lineages and perform a cluster analysis. Clusters of strains
with identical genotyping patterns were considered as an indicator for the rate of recent transmission.
Results: The population structure was found to be highly diverse: out of the 244 MTBC isolates
59.0% were classified into nine previously described lineages: Dehli/CAS (38.9%), Haarlem (8.6%),
Ural (3.3%), LAM (3.3%), TUR (2.0%), X-type (1.2%), S-type (0.8%), Beijing (0.4%) and Uganda II
(0.4%). Interestingly, 31.6% of the strains investigated were grouped into four new lineages and were
named as Ethiopia_3 (13.1%), Ethiopia_1 (7.8%), Ethiopia_H37Rv like (7.0%) and Ethiopia_2 (3.7%)
lineages. The remaining 9.4% of the isolates could not be assigned to the known or new lineages.
Overall, 45.1% of the isolates were grouped in clusters, indicating a high rate of recent transmission.
Similarly, 66.7% of MDR strains were grouped in clusters.
Conclusion: This study confirms a highly diverse MTBC population structure, the presence of new
phylogenetic lineages and a predominance of the Dehli/CAS genotype in Northwest Ethiopia. The
high rate of recent transmission indicates defects of the TB control program in Northwest Ethiopia.
This emphasizes the importance of strengthening laboratory diagnosis of TB, intensified case finding
and treatment of TB patients to interrupt the chain of transmission.
Key words: Mycobacterium tuberculosis, molecular epidemiology, transmission dynamics
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Introduction
Despite the existence of anti-tuberculosis drugs for the last 60 years, tuberculosis (TB) continues to be
a major threat worldwide. In 2009, WHO estimated the global incidence of TB with 9.4 million cases.
Most of the estimated number of TB cases occurred in Asia (55%) and Africa (30%). The 22 high
burden tuberculosis countries account for 81% of all estimated cases worldwide (1). Ethiopia ranks
seventh among the world’s 22 high-burden tuberculosis countries. The country had 314, 267 TB cases
in 2007, with an estimated incidence rate of 378 cases per 100,000 population (2). According to the
Ministry of Health hospital statistics data, tuberculosis is one of the leading causes of morbidity, the
fourth most common cause of hospital admission, and the second most common cause of hospital
death in Ethiopia (3). Additionally, the countrywide anti-TB drug resistance survey conducted in 2005
showed that the prevalence of multidrug resistant TB (MDR, resistance to at least isoniazid [INH] and
rifampicin [RMP]) was 1.6% and 11.8% among new untreated and previously treated TB cases,
respectively (4). These data show that the TB epidemic is a significant public health threat in Ethiopia,
however, detailed epidemiological data assisted by molecular strain typing that pinpoint actual
weaknesses in TB control and underlying disease dynamics are not available yet.
Molecular strain typing (genotyping) has contributed significantly to the understanding of TB
epidemiology and has helped to improve TB control by providing information on transmission
dynamics (5), determining the importance of reactivation versus exogenous reinfection (6),
investigating/confirming outbreaks (7), confirmation of laboratory cross contamination (8) and to
identify the clonal spread of successful clones, including multi-drug-resistant ones (9). Furthermore,
molecular typing has revealed that the MTBC has a diverse population structure with manifold
lineages that show large differences in their geographical occurrence and, also, in their pathobiological
properties e.g. development and spread of drug resistance (10).
In Ethiopia, few molecular epidemiological studies have been done so far only for the isolates from
patients in the capital city, Addis Ababa (11-13). Studies were limited by small sample size,
incomplete epidemiological information and/or use of a genotyping method with low strain
discriminatory capacity. Recent data are only available from an MDR strain targeted study from year
2006. However, the strains were investigated by spoligotyping only, allowing neither for high
resolution phylogenetic strain classification nor for analysis of transmission dynamics (11).
In this study, we used a combination of mycobacterial interspersed repetitive unit-variable number
tandem repeat (MIRU-VNTR) typing and spoligotyping to investigate a large collection of MTBC
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strains isolated from patients living in Amhara region, Northwest Ethiopia. In contrast to classical
molecular typing methods such as IS6110 DNA fingerprint and spoligotyping, 24-loci MIRU-VNTR
genotyping allows for a high-resolution discrimination of isolates for epidemiological studies and a
valid phylogenetic strain classification (14). The data obtained are likely to allow for new insights into
population structure and transmission dynamics, thus also revealing urgently needed data to improve
TB control in Ethiopia.
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Materials and Methods
Study design, area and study period
A total of 260 smear positive pulmonary tuberculosis patients diagnosed at Gondar Hospital, Gondar
Health Center, Metemma Hospital, Bahir Dar Hospital and Debre Markos Hospital between March
2009 and July 2009 were included in this study. For all study subjects, information on the socio-
demographic data, history of previous tuberculosis treatment, HIV status and the drug susceptibility
patterns of the M. tuberculosis isolates was available. Informed consent was obtained from the study
subjects and the single morning sputum sample and 5ml venous blood sample were collected prior to
commencing TB treatment. A structured questionnaire was used to classify patients into new and
previously treated tuberculosis cases and to collect socio-demographic data of the study subjects.
Institutional ethical clearance was obtained from the research and publication committee of University
of Gondar, Ethiopia. Specimens were stored and transported to the Institute of Medical Microbiology
and Epidemiology of Infectious Diseases, University Hospital of Leipzig, Germany as described
previously (15) for culture and drug susceptibility testing.
Culture and drug susceptibility testing (DST)
Isolation, identification and DST were performed as described previously (16). Briefly, specimens
were processed and cultured according to the Deutsches Institut für Normung (DIN) recommendations
(17) using Lowenstein Jensen (L-J) media, Gottsacker media and the BacT/ALERT 3D system.
Isolates were identified by DNA hybridization technology (GenoType® MTBC; Hain Lifescience,
Nehren, Germany) following the manufacturer’s instructions. DST for first line drugs including
isoniazid, rifampicin, streptomycin, ethambutol and pyrazinamide was performed by BacT/ALERT 3D
system (BioMerieux, S.A , France) according to the methods developed for MB/BacT system (18, 19).
DST for second line drugs including fluoroquinolones (FLQ) (ofloxacin & moxifloxacin) and
aminoglycocides (AM) /cyclic peptides (CM) (capreomycin, viomicin/kanamycin and amikacin) was
performed using DNA hybridization technology on nitrocellulose strips (GenoType® MTBDRsl; Hain
Lifescience, Nehren, Germany) following the manufacturer’s instructions. Patients’ serum samples
were screened for HIV-1 and HIV-2 using Vironostika HIV Uni-Form II Ag/Ab enzyme-linked
immunosorbent assay (ELISA) kit (Bio-Merieux, Boxtel, The Netherlands) following the
manufacturer’s instructions.
DNA extraction.  DNA was extracted from all isolates by heating mycobacterial pellets obtained from
liquid culture, suspended in 200 µL 10 mM Tris-HCl, 1 mM EDTA (pH 7.0) buffer at 950C for 20
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minutes followed by 15 minutes sonication in a sonicating water bath. The suspension was centrifuged
at 15,000 rpm for 1 minute, and the supernatant was stored at -200C until used.
Genotyping
All isolates were analyzed by spoligotyping technique as described previously (20) and by 24 - loci
MIRU-VNTR genotyping technique as described previously (14). Briefly, for MIRU-VNTR
genotyping, 24 loci were amplified by using the MIRU-VNTR typing kit (Genoscreen, Lille, France).
Analyses of the PCR products were performed by using the Rox-labeled MapMarker 1,500 size
standard (BioVentures, Inc., Murfreesboro, VT) for mix 5 and 1000 size standard (BioVentures, Inc.,
Murfreesboro, VT) for other mixes (mix 1-4, and mix 6-8), and using the ABI 3130 XL sequencer
with 16 capillaries (Applied Biosystems, Foster City, CA). Sizing of the PCR fragments and
assignment of the various VNTR alleles were done by using the GeneMapper software version 4.0
(Applied Biosystems, Foster City, CA).
The MIRU-VNTR 24-loci profiles and spoligotyping patterns were used to classify the strains into
main phylogenetic lineages by using the reference strain collection and identification tools available
online at www.miru-vntrplus.org (21). Briefly, a stepwise identification procedure was carried out as
follows. The strains were first classified by the simple match approach that is based on the best match
with strains of the reference database. The cut of distance for lineage assignment was set to 0.17. In a
second step, phylogenetic tree identification was carried out. Additionally, for each MIRU-VNTR 24-
loci pattern a unique MLVA 15-9 code was assigned by using the MIRU-VNTRplus nomenclature.
Cluster analyses of molecular typing data were performed with the Bionumerics software (version 6.6;
Applied Maths, Sint-Martens-Latem, Belgium) according to the manufacturers’ instructions.
Similarities of genotyping patterns among strains were calculated by using the categorical coefficient.
A dendrogram was generated by using the unweighted pair group method with arithmetic averages
(UPGMA). Minimum spanning tree analysis was done based on MIRU-VNTR typing data by using
the categorical coefficient. For the cluster analysis, a cluster was defined as a minimum of two strains
harbouring identical genotype pattern (using composite data, MIRU-VNTR 24-loci and spoligotyping)
from different patients belonging to the study subjects. The recent transmission index (RTI) was
calculated as (number of clustered patients - number of clusters)/total number of patients.
Determination of the discriminatory power of the genotyping methods (MIRU-VNTR 24-loci typing
and spoligotyping) was calculated using the Hunter-Gaston Discriminatory Index (HGDI) as
previously described (22).
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Statistical analysis
All laboratory data were entered, cleared and analyzed using SPSS version 13 statistical package
software (SPSS Inc., Chicago, IL). Categorical data were compared by the chi-square test or the fisher
exact test, when expected cell sizes (n) were smaller than 5. Two models were constructed in a logistic
regression analysis using clusters and anti-TB drug resistance as the respective outcome variables. In
order to determine independent risk factors, odds ratios (OR) and 95% confidence intervals (CI) were
calculated by using logistic regression analysis for demographic (gender, age, address and religion),
epidemiologic (previous treatment and HIV status), and microbiological variables (drug resistance,
and infection by M. tuberculosis lineages). P-values less than 0.05 were considered statistically
significant.
Publication IV
38
RESULTS
Demographic characteristics
A total of 260 M. tuberculosis isolates were utilized to carry out MIRU-VNTR 24-loci and
spoligotyping analysis. Out of these, 16 isolates were excluded from the final analysis as for 15 of
these, no PCR amplicon was obtained at two or more loci and one multidrug resistant isolate was
identified as a mixture of two independent strains during MIRU-VNTR typing. An occasional lack of
PCR amplification of some loci has been reported in previous studies (14, 23). This might be
explained by chromosomal deletion, nucleotide polymorphisms in the sequences complementary to
PCR primers (24), or insufficient DNA quality. A mixture of two independent strains was also defined
by the presence of double alleles at two or more loci (14, 25). Isolates with no PCR amplicon at only
one locus were treated as missing data at the respective loci and included into the analysis. These
observations remained the same even after repeated testing with freshly prepared materials. For the
remaining 244 isolates, valid genotyping data were obtained and used for further analyses.
Some demographic data of the study subjects and complete drug susceptibility test results for the
isolates used herein were included in our previous report (16). Briefly, the mean age ± the standard
deviation of 244 study subjects was 31.6 ± 12.5 (range, 68 years), and 58.2% patients were male.
Nearly all patients, 98.8% were Amhara by ethnicity, and 97.5% patients were Christian by religion.
Of all study subjects, 17.6% patients were previously treated cases and 25.4% patients were HIV co-
infected. Overall, 40 patients (16.4%) had a strain showing resistance to at least one first line drug
tested. Thirty-four strains (13.9%) were resistant to INH, 14 (5.7%) strains were resistant to RMP, and
12 (4.9%) were MDR (Table 1). All isolates were susceptible to second line anti-TB drugs tested.
Table 1: Demographic characteristics of the study subjects, drug resistance patterns, phylogenetic
lineages and their association with clustering
Genotyping patternsCharacteristics Total
N (%) Clustered Unique
OR (95% CI) p-value
Gender
Male 142 (58.2) 63 79 0.9 (0.6-1.6) 0.791
Female 102 (41.8) 47 55 1
Age group
(years)
< 45 210 (86.1) 93 117 0.8 (0.4-1.6) 0.534
>45 34 (13.9) 17 17 1
Address
Rural 112 (45.9) 52 60 1.1 (0.7-1.8) 0.697
Urban 132 (54.1) 58 74 1
Religion
Christian 238 (97.5) 108 130 1.7 (0.3-9.2) 0.693*
Muslim 6 (2.5) 2 4 1
Previous TB
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treatment
Yes 43 (17.6) 26 17 2.1 (1.1-4.2) 0.026
No 201 (82.4) 84 117 1
HIV status
Positive 62 (25.4) 24 38 0.7 (0.4-1.3) 0.243
Negative 182 (74.6) 86 96 1
Isoniazid
Resistant 34 (13.9) 22 12 2.5 (1.2-5.4) 0.013
Sensitive 210 (86.1) 88 122 1
Rifampicin
Resistant 14 (5.7) 9 5 2.3 (0.7-7.1) 0.137
Sensitive 230 (94.3) 101 129 1
Streptomycin
Resistant 26 (10.7) 19 7 3.8 (1.5-9.4) 0.002
Sensitive 218 (89.3) 91 127 1
Ethambutol
Resistant 18 (7.4) 14 4 4.7 (1.5-14.9) 0.004
Sensitive 226 (92.6) 96 130 1
Pyrazinamide
Resistant 12 (4.9) 8 4 2.5 (0.7-8.7) 0.123
Sensitive 232 (95.1) 102 130 1
Resistant to one
or more FLD
Resistant 40 (16.4) 25 15 2.3 (1.2-4.7) 0.015
Sensitive 204 (83.6) 85 119 1
MDR-TB
Yes 12 (4.9) 8 4 2.5 (0.7-8.7) 0.123
No 232 (95.1) 102 130 1
Resistant to all
FLD
Yes 9 (3.7) 8 1 10.4 (1.3-84.7) 0.012*
No 235 (96.3) 102 133 1
M. tuberculosis
lineages
Dehli/CAS 95 (38.9) 51 44 6.2 (1.7-22.6) 0.006
Ethiopia_3 32 (13.1) 23 9 13.6 (3.2-58.3) <0.001
Haarlem 21 (8.6) 9 12 4.0 (0.9-18.0) 0.071
Ethiopia_1§ 19 (7.8) 3 16 1 -
Ethiopia_H37Rv
like
17 (7.0) 9 8 6.0 (1.3-28.5) 0.024
Ethiopia_2 9 (3.7) 4 5 4.3 (0.7-25.9) 0.115
URAL 8 (3.3) 0 8 - -
LAM 8 (3.3) 3 5 3.2 (0.5-21.2) 0.228
TUR 5 (2.0) 4 1 21.3 (1.7- 263.7) 0.017
X-type 3 (1.2) 0 3 - -
S-type 2 (0.8) 0 2 - -
Beijing 1 (0.4) 0 1 - -
UgandII 1 (0.4) 0 1 - -
Not defined 23 (9.4) 4 19 1.1 (0.2-5.8) 0.890
Total 244 (100.0) 110 (45.1) 134 (54.9) - -
*=Fisher exact test, FLD= First line anti-TB drugs, MDR= Multidrug resistant, §= reference category,
LAM= M. tuberculosis Latin American Mediterranean
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Population structure and cluster analysis
According to the phylogenetic classification of 244 M. tuberculosis isolates, 144 (59.0%) were
classified into previously described lineages as follows: 95 (38.9%) strains were Dehli/CAS, 21
(8.6%) Haarlem, 8 (3.3%) Ural, 8 (3.3%) LAM (Latin American Mediterranean), 5 (2.0%) TUR, 3
(1.2%) X-type, 2 (0.8%) S-type, 1 (0.4%) Beijing and 1 (0.4%) Uganda II lineage. Interestingly, 77
(31.6%) of the isolates were appear to form four previously undefined lineages, the largest of which
having 32 (13.1%) isolates was named Ethiopia_3, followed by a branch with 19 (7.8%) isolates and
was named as Ethiopia_1, a third branch with 17 (7.0%) isolates that were closely related to the
laboratory strain H37Rv was named Ethiopia_H37Rv like, and the fourth branch with 9 (3.7%) strains
was named as Ethiopia_2. The remaining 23 (9.4%) isolates could not be assigned to a known
phylogenetic lineage or a new lineage (Fig. 1, Table 1). To confirm this strain classification, we
calculated a minimum-spanning tree (MST) based on the MIRU-VNTR 24- loci data. The MST (Fig.
2) confirmed the classification according to UPGMA tree-based analysis (Fig. 1) and by comparison
with the MIRU-VNTRplus reference database. All lineages suspected from dendrogram-based
analysis were also detected as clonal complexes in the MST, including the newly described genotypes
(Fig.2).
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FIG. 1. Radial UPGMA tree based on the copy numbers of MIRU-VNTR 24-loci. The tree was
calculated by using the MIRU-VNTRplus website. Abbreviations: LAM=M. tuberculosis Latin
American Mediterranean.
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FIG. 2. Minimum spanning tree based on the diversity of MIRU-VNTR 24-loci data. The different
complexes identified are coloured (maximum neighbour distance: four changes; minimum size: two
MIRU-VNTR types) by the set of 24-loci among the 244 M. tuberculosis strains analyzed. The size of
each circle is proportional to the number of MIRU-VNTR types belonging to a particular complex.
LAM=M. tuberculosis Latin American  Mediterranean.
Cluster analysis revealed that 110 of the 244 strains (45.1%) shared a genotyping pattern with at least
one other isolate and were grouped in 36 clusters ranging in size from 2 to 13 strains, resulting in a
resent transmission index (RTI) of 30.3%. The remaining strains were discriminated into 134 unique
genotypes. Strains were also assigned to MLVA MtbC15-9 types (Table 2, Fig.S1 in the supplemental
material). The largest cluster (n = 13; cluster 5: MLVA MtbC15-9 type 594-15) is formed by the
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Ethiopia-3 genotype, followed by the second largest clusters formed by strains of the Dehli/CAS
genotype (n = 8, cluster 19: MLVA MtbC15-9 type 1557-32), indicating ongoing transmission of these
strains.
Of 12 MDR strains, 8 (66.7%) were in 5 clusters; three clusters contained exclusively 2 MDR strains
each, indicating successful transmission of MDR strains within the community, one cluster contained
one MDR strain and one INH, EMB and STM resistant strain, and one cluster contained one MDR,
one INH and STM resistant strain and three fully susceptible strains, indicating transmission of INH
resistant strains that later developed MDR.
Table 2. Discriminatory capacities of spoligotyping and MIRU-VNTR 24-loci, alone or in
combination for M. tuberculosis isolates from Ethiopia
HGDI= Hunter-Gastone discriminatory index, highest degree for HGDI is 1 that shows highest
discriminatory power of a method, RTI= Recent transmission index
Factors associated with strain clustering
When the clustering rates were stratified for strains of different phylogenetic lineages, we observed
striking differences. The odds of clustering was 21-fold higher among TUR lineage (4 out of 5 strains)
(P=0.017), 14-fold higher among Ethiopia_3 lineage (23 out of 32 strains) (P<0.001), 6-fold higher
among Dehli/CAS lineage (51 out of 95 strains) (P=0.006) and 6-fold higher among Ethiopia_H37Rv
like lineage (9 out of 17 strains) (P= 0.024) compared to Ethiopia_1 linage (3 out of 19 strains) (Table
1).
The odds of clustering was also 2-fold higher among strains from previously treated cases (26 out of
43 strains) (P=0.026) compared to strains from the new cases, nearly 3-fold higher among INH
Genotyping method No. of
different
patterns
No. of
isolates with
unique
pattern
No. of
cluster
s
No. of
isolates in
clusters
Clusteri
ng rate
(%)
RTI
(%)
HGDI
Spoligotyping 69 43 26 201 82.4 64.8 0.88
MIRU-VNTR 24-loci 161 124 37 120 49.2 34.0 0.97
MIRU-VNTR 24-loci +
Spoligotyping
170 134 36 110 45.1 30.3 0.97
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resistant strains (22 out of 34 strains) compared to INH susceptible strains (P=0.013), nearly 4-fold
higher among STM resistant strains (19 out of 26 strains) (P=0.002) compared to STM susceptible
strains, and nearly 5-fold higher among EMB resistant strains (14 out of 18 strains) (P=0.004)
compared to EMB susceptible strains. Additionally, strains that were resistant to one or more first line
anti-TB drugs had 2-fold higher odds of clustering (25 out of 40 strains) (P=0.015) compared to fully
susceptible strains, and strains that were resistant to all first line anti-TB drugs had 10-fold higher odds
of clustering (8 out of 9 strains) (P=0.012) compared to strains that were susceptible to at least one
first line anti-TB drugs. However, multidrug resistance was not a significant risk factor for clustering
(8 out of 12 strains) (OR=2.5, P = 0.123) compared to non multidrug resistant strains (Table 1).
Interestingly, more than 50% of MDR strains were classified as the Haarlem lineage (Table 3).
Although the numbers are small, the odds of having multidrug resistance was 22-fold higher among
patients with a Haarlem strain (P <0.001) compared to patients with the non Haarlem strains and the
odds of resistance to all first line anti TB-drugs was 10-fold higher among patients with a Haarlem
strain (P=0.004) compared to patients with non Haarlem strains. Similarly, significantly higher risk of
resistance to INH (P=0.017), RMP (P<0.001), STM (P=0.015), EMB (P=0.002) or PZA (P=0.002)
was observed among patients with a Haarlem lineage compared to patients with the non Haarlem
strains (Table 4).
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Table 3: Anti-TB drug resistance, patients’ history of previous TB treatment and HIV status stratified
for M. tuberculosis genotypes
n= number, RFLD= Resistant to all first line anti-TB drugs, MDR= Multidrug resistant, LAM= M.
tuberculosis Latin American Mediterranean, PT= previously treated cases, INH=isoniazid,
RMP=rifampicin, STM= streptomycin, EMB= ethambutol, PZA= pyrazinamide, + = positive
Anti-TB drugs resistanceM.tuberculosis
genotypes (n)
INH
N (%)
RMP
N (%)
STM
N(%)
EMB
N(%)
PZA
N(%)
MDR
N (%)
RFLD
N (%)
PT
N (%)
HIV +
N (%)
Dehli/CAS (95) 10 (10.0) 3 (3.3) 10 (10.5) 7 (7.4) 2 (2.1) 2 (2.1) 2 (2.1) 19 (20.0) 24 (25.3)
Ethiopia_3 (32) 10 (31.0) 3 (9.4) 6 (18.8) 5 (15.6) 4 (12.5) 3 (9.4) 3 (9.4) 7 (21.9) 4 (12.5)
Haarlem (21) 7 (33.33) 7 (33.3) 6 (28.6) 6 (28.6) 5 (23.8) 7 (33.3) 4 (19.0) 2 (9.5) 7 (33.3)
Ethiopia_1 (19) 1 (5.3) 0 1 (5.3) 0 1 (5.3) 0 0 5 (26.3) 4 (21.1)
Ethiopia_H37Rv
like (17)
2 (11.8) 0 1 (5.9) 0 0 0 0 3 (17.6) 6 (35.3)
Ethiopia_2 (9) 0 0 0 0 0 0 0 1 (11.1) 1 (11.1)
URAL (8) 0 0 0 0 0 0 0 0 3 (37.5)
LAM (8) 0 0 0 0 0 0 0 0 2 (25.0)
TUR (5) 2 (40.0) 0 1 (20.0) 0 0 0 0 1 (20.0) 2 (40.0)
X-type (3) 1 (33.3) 0 1 (33.3) 0 0 0 0 0 2 (66.7)
S-type (2) 0 0 0 0 0 0 0 0 0
Beijing (1) 0 0 0 0 0 0 0 0 0
UgandII (1) 0 0 0 0 0 0 0 0 0
Not defined (23) 1 (4.3) 1 (4.3) 0 0 0 0 0 5 (21.7) 7 (30.4)
Total  (244) 34 (13.9) 14 (5.7) 26 (10.7) 18 (7.4) 12 (4.9) 12 (4.9) 9 (3.7) 43 (17.6) 62 (25.4)
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Table 4: M. tuberculosis Haarlem lineage and its association with anti-tuberculosis drug resistance
M. tuberculosis lineagesDrug resistance
Haarlem
(n)
Non Haarlem
(n)
OR (95% CI) P-value*
Isoniazid
R 7 27 3.6 (1.3-9.8) 0.017
S 14 196 1
Rifampicin
R 7 7 15.4 (4.7-50.2) <0.001
S 14 216 1
Streptomycin
R 6 20 4.1 (1.4-11.6) 0.015
S 15 203 1
Ethambutol
R 6 12 7.0 (2.3-21.4) 0.002
S 15 211 1
Pyrazinamid
R 5 7 9.6 (2.7-33.8) 0.002
S 16 216 1
MDR-TB
Yes 7 5 21.8 ( 6.1-77.5) <0.001
No 14 218 1
Resistant to all
FLD
Yes 4 5 10.3 (2.5-41.8) 0.004
No 17 218 1
R = resistant, S = sensitive, n = number, * = Fisher exact test, FLD = First line anti-TB drugs, MDR-
TB = multidrug resistant tuberculosis
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Discussion
Recent advances in molecular strain typing such as the development of 24-loci MIRU-VNTR typing
provide a powerful tool to analyze MTBC population structure and transmission dynamics locally and
on the global level, which provides valuable information for the development of effective tuberculosis
control policy. In this study we present the first in-depth analysis of the population structure of M.
tuberculosis strains in Ethiopia based on high-resolution MIRU-VNTR 24-loci typing and
spoligotyping. Our data confirm a highly diverse population structure that comprises, thirteen
phylogenetic lineages, four of which were not described before. Furthermore, our data indicate a high
rate of ongoing recent transmission, of which the spread of MDR strains is of special importance.
Only few in-depth analyses of the population structure of M. tuberculosis strains are available from
Africa. Most of the investigations are limited by sample size, available epidemiological information,
and/or by the genotyping technique used. Previous reports have shown that studies based on
spoligotyping only are limited by the inherent problems to perform a valid phylogenetic classification
of a large proportion of isolates in a certain area due to high rates of homoplasy (26, 27). On the
contrary, the MIRU-VNTR 24-loci typing method applied in our study has the advantage to allow for
high-resolution genotyping needed for molecular epidemiological studies and, simultaneously, for
valid phylogenetic strain classification enabling screening for new phylogenetic lineages/clonal
complexes (14).
Using this method, 90.6% of the strains investigated were classified to M. tuberculosis lineages; of
which, 58.9% were described before and 31.6 % were newly described in this study. We documented
that M. tuberculosis Dehli/CAS is the predominant phylogenetic lineage in Ethiopia, accounting 39%
of investigated strains. Similarly, a previously published study from the capital city of Ethiopia
showed that 43.5% of the strains were CAS genotype (11), and a study from Sudan (28) also showed
that M. tuberculosis Dehli/CAS is the predominant lineage (49%) of investigated strains. The
Dehli/CAS lineage is essentially localized in the Central Asia and Middle-East, more specifically in
India (29). Two hypotheses could explain the presence of high Dehli/CAS lineage in Ethiopia: (i) the
large Indian and Chinese communities in Ethiopia due to the growing economic partnerships between
Ethiopia and the two Asian countries, India and China may have contributed in the introduction of this
lineage; or (ii) this lineage could  have emerged from Ethiopia and migrated through Asia, this
hypothesis is in agreement with the suggestion that East Africa is the origin of M. tuberculosis
complex species (30).
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Additionally, we confirmed the presence of previously undefined phylogenetic lineages named as
Ethiopia_3, Ethiopia_1, Ethiopia_H37RV-like and Ethiopia_2 that were clearly defined by tree based,
as well as by minimum spanning tree-based analysis. However, comparison with other studies is
hampered by the fact that they are mainly based on IS6110 DNA fingerprint and/or spoligotyping
analysis hindering a valid analysis of the population structure and standardized comparisons base on
MIRU-VNTR nomenclature. Thus, the actual picture of M. tuberculosis population diversity in
African high-incidence settings is largely incomplete and needs a systematic investigation with
phylogenetic useful genotyping methods.
This study also showed a significant association between Haarlem strain infection and multi-drug
resistance, resistance to all first line anti-TB drugs and resistance to each first line anti-TB drugs
including INH, RMP, STM, EMB and PZA. Similarly, a previous study from Tunisia showed that the
Haarlem family genotype has a similar relationship with drug resistance and rapid clonal expansion
(31). The association between drug resistance and the Beijing genotype is also well documented in
previous studies (32, 33). The association of these genotype families with drug-resistant outbreaks
clearly demonstrates their epidemic potential (31, 34). From TB-control point of view, it is relevant to
understand whether specific genotype families are overrepresented among drug-resistant cases and, in
particular, if these resistant strains are successfully transmitted within the community.
Although the interpretations of clustering results remain somewhat controversial, it is accepted that
clustering is a marker for recent transmission (35-37). By using degree of recent TB transmission in a
study population, one can estimate the efficacy of the TB control program (35). Both high TB
incidence and the current drug-resistance rates in Ethiopia are indicative of defects of the TB control
program (2, 4, 16). Supporting this suggestion, we found a high rate of clustering, 45.1% of the total
strains investigated. This is in agreement with the previous reports from the capital city of Ethiopia
that showed clustering rate of 41.2% (13) and 48.1% (12).
Even more important, we confirm elevated cluster rate in drug resistant strains in general as well as for
MDR strains.  Similarly, there was a significant association between recent transmission and patients
with the history of previous TB treatment, infection with INH resistant strains, STM resistant strains,
EMB resistant strains, strains resistant to one or more first line anti-TB drugs and patients with strains
resistant to all first line anti-TB drugs. This might be due to the fact that, in Ethiopia there is no culture
and drug susceptibility testing facility for routine diagnosis of drug resistance, thus, drug resistant-TB
is only diagnosed after prolonged treatment with first-line anti-TB drugs and clinical recognition that
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treatment has failed. Treatment of drug-resistant TB with standard first line drugs, instead of a regimen
designed according to the resistance pattern has several potential adverse consequences: patients
remain on inadequate treatment longer, increasing the risk of treatment failure or death; selection of
drug resistant strains and patients remain infectious, promoting transmission to close contacts (38).
These data indicate a successful transmission of drug resistant and MDR strains in the community, a
situation that needs to be carefully monitored in the future to determine extensive transmission of
resistant strains early enough to avoid more significant problems for TB control as already eminent in
several parts of Eastern Europe or South Africa (39, 40).
Interestingly, we present evidence of significant association between recent transmission and the
Dehli/CAS, Ethiopia_3, TUR and Ethiopia_H37Rv like strain infections. Similarly, Gagneux et al.
have recently proposed that the major M. tuberculosis lineages have evolved so as to become adapted
to specific host genetic backgrounds and are much more likely to transmit and cause disease among
patients of the same ethnicity (41).
In conclusion, our study confirms a highly diverse population structure of M. tuberculosis, the
presence of phylogenetic lineages that were not described before and a predominance of the
Dehli/CAS genotype in the Amhara region, Northwest Ethiopia. Our study also showed a significant
association between Haarlem strain infection and resistance to first line anti-TB drugs including
multidrug reissuance. The high rate of recent transmission underlines active transmission of M.
tuberculosis including drug-resistant strains, and consequently the inefficacy of TB control program in
the study area. This emphasizes the importance of strengthening laboratory diagnosis of TB including
culture and drug susceptibility testing, intensified case finding and treatment of TB patients according
to the ongoing DOTS program to interrupt the chain of transmission within the community.
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Summary
Ethiopia ranks seventh among the world’s 22 high-burden tuberculosis countries. The emergence of
drug resistant M. tuberculosis strains is one of the most important threats to tuberculosis control
program in the country. The high prevalence of HIV, widespread poverty and overcrowding have
created an environment which made tuberculosis a formidable threat in Ethiopia. For proper treatment
and control of tuberculosis, WHO is recommending countries to expand their capacity for culture and
drug-susceptibility testing (DST). However, culture and drug susceptibility testing of M. tuberculosis
is being done only in the national reference laboratory, in the capital city, Addis Ababa. The successful
isolation of M. tuberculosis from remote settings requires proper collection, storage and transportation
of sputum specimens to reference laboratories. To ensure high yield of positive cultures, WHO
recommends that two sputum specimens be collected from remote areas and transported to reference
laboratories without delay. There may be a substantial cost associated with handling, transportation
and processing of two sputum specimens from each patient. In addition, sputum preservatives, such as
0.6% cetylpyridinium bromide (CPB) or 1% cetylpyridinium chloride (CPC), are recommended when
delay is unavoidable. CPC, the most commonly used preservative keeps tubercle bacilli viable only for
up to 8 days. Moreover, previous studies have shown the negative effect of CPC on microscopic
examination and culture results. Therefore, a simple and inexpensive method for sputum storage that
preserves the viability of tubercle bacilli for long periods of time will be useful for proper laboratory
diagnosis, epidemiological studies and drug resistance surveillance from remote settings.
Due to the lack of diagnostic facility in the country, drug resistant TB is diagnosed after prolonged
treatment with first-line anti-TB drugs and clinical recognition that treatment has failed. Treatment of
drug-resistant TB with standard first-line drugs, instead of a regimen designed according to the
resistance pattern has several potential adverse consequences: patients remain on inadequate treatment
longer, increasing the risk of treatment failure or death; selection of drug resistant strains and patients
remain infectious, promoting transmission to close contacts. In order to optimize standard anti-
tuberculosis drug therapy and to increase the success of TB control programs, it is important to know
the pattern of drug resistance in a country. However, only limited data on the level and risk factors of
first line and second line anti-TB drug resistance are available in Ethiopia.
WHO is also recommending countries to consider new, molecular-based assays for the diagnosis of
drug resistance because of their high speed, sensitivity and specificity. Molecular methods that have
been developed to detect drug resistance include the GenoType® MTBDRplus for detection of
isoniazid (INH) and rifampicin (RMP) resistance and the GenoType® MTBDRsl for detection of
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resistance against ethambutol (EMB), fluoroquinolones (ofloxacin and moxifloxacin), and
aminoglycosides/cyclic peptides (capreomycin, viomicin/kanamycin and amikacin) (Hain Lifescience,
Nehren, Germany). The performance of GenoType® MTBDRplus and GenoType® MTBDRsl assays
has been studied in several laboratories of other countries. However, there is a wide variation in
circulating M. tuberculosis strains worldwide and false negative results reported due to unique genetic
mutations, affecting the performance of molecular assays for drug susceptibility testing. Therefore,
analysis of gene mutations associated with resistance to anti-tuberculosis drugs and assessment of the
performance of molecular methods for drug resistance testing in different settings are needed to ensure
acceptable performance of the assays.
Recent advances in molecular technology such as the development of mycobacterial interspersed
repetitive unit-variable number tandem repeat (MIRU-VNTR) 24-loci typing and spoligotyping
methods provide a powerful tool to analyze M. tuberculosis genotypes and transmission dynamics,
which should be valuable for development of effective tuberculosis control policy. In Ethiopia limited
epidemiological studies have been done so far only for isolates from patients in the capital city, Addis
Ababa. Moreover, studies were limited by small sample size, incomplete epidemiological information
and use of a genotyping method with low strain discriminatory capacity.
Lack of the aforementioned information makes the tuberculosis prevention and control efforts difficult
in Ethiopia. Therefore, this study was done to fill the information gaps that are urgently needed for
designing effective tuberculosis prevention and control strategies in the country.
Publication I: To investigate the recovery rate of M. tuberculosis from smear positive single morning
sputum specimens subjected to long term storage at -200C, single morning sputum samples were
collected from all smear-positive tuberculosis patients diagnosed at Gondar Hospital, Gondar Health
Center, Metemma Hospital, Bahir Dar Hospital, and Debre Markos Hospital in Northwest Ethiopia
between March and July 2009. Specimens were stored at -20°C at the study sites and sent to the
mycobacteriology laboratory at the University Hospital, Leipzig, Germany, where specimens were
processed and inoculated into the BacT/Alert 3D system, Lowenstein-Jensen and Gottsacker media.
Ice packs were added in the package of the specimens during transport. A total of 319 patients were
enrolled in this study. The median specimen storage time was 132 days (range, 16 to 180 days). Of all
specimens, 287 (90.0%) were culture positive. The length of time of sputum storage had no significant
effect on the recovery rate of M. tuberculosis in all culturing systems. However, lower degree of smear
positivity and lower sputum volume (< 2ml) were significant factors for a low recovery rate. In
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conclusion, single morning sputum specimens collected at remote settings stored at -20°C for long
periods of time without the addition of chemical preservatives can yield a high recovery rate. These
findings suggest a simple and cost-effective method of sputum storage for epidemiological and drug
resistance studies in low resource countries.
Publication II: To assess the level and risk factors for first and second line anti-TB drug resistance,
DST for first-line drugs including isoniazid, rifampicin, streptomycin, ethambutol and pyrazinamide
was performed by BacT/ALERT 3D system. DST to second-line drugs including fluoroquinolones and
aminoglycocides/cyclic peptides was performed using GenoType(R) MTBDRsl. Of 260 M.
tuberculosis isolates investigated, 41 (15.8%) were resistant to at least one first-line drug, 13 (5.0%)
were multidrug resistant (MDR) and 9 (3.5%) were resistant to all first-line drugs. Any resistance to
isoniazid, rifampicin, streptomycin, ethambutol and pyrazinamide was 36 (13.8%), 15 (5.8%), 26
(10.0%), 19 (7.3%) and 12 (4.6%), respectively. MDR-TB was 8/214 (3.7%) among new cases and
5/46 (10.9%) among previously treated cases. All isolates were susceptible to second-line drugs.
Previously treated cases and patients diagnosed at Metemma hospital had significantly higher level of
drug resistance compared with new cases and patients from Debre Markos hospital, respectively. In
conclusion, a substantial number of new and previously treated cases harbour MDR-TB. We
recommend DST at least for previously treated cases, patients remain smear positive at the end of the
second month of treatment and patients with close contact to MDR-TB cases. Moreover, improved
infection control measures need to be implemented in Ethiopia.
Publication III: The performance of the GenoType® MTBDRplus for detection of resistance to INH,
RMP and MDR and GenoType® MTBDRsl assay for detection of EMB resistance was evaluated
compared to the BacT/ALERT 3D system as a reference method, and the frequency of gene mutations
associated with resistance to INH, RMP and EMB was analyzed among 260 M. tuberculosis isolates.
The GenoType(R) MTBDRplus assay had a sensitivity of 92% and specificity of 99% to detect INH
resistance, and 100% sensitivity and specificity to detect RMP resistance and MDR. The GenoType(R)
MTBDRsl assay had a sensitivity of 42% and specificity of 100% for EMB resistance. Of 260 M.
tuberculosis isolates investigated by the molecular methods, mutations conferring resistance to INH,
RMP, or EMB were detected in 35 (13.5%), 15 (5.8%), and 8 (3.1%) isolates, respectively, while
mutations conferring resistance to both INH and RMP, multidrug resistance were present in 13 (5.0%)
of the isolates. Of 35 INH resistant strains, 33 (94.3%) had mutations in the katG gene at Ser315Thr 1
and two strains had mutation in the inhA gene at C15T. Among 15 RMP resistant isolates, 11 (73.3%)
had rpoB gene mutation at Ser531Leu, one at His526Asp, and three strains had mutations but the
Summary
58
amino acid changes could not be detected by this method. Of 8 EMB resistant strains, two had
mutations in the embB gene at Met306Ile, one at Met306Val, and five strains had mutations but the
amino acid changes could not be detected. In conclusion, the GenoType(R) MTBDRplus assay is a
sensitive and specific tool for diagnosis of resistance to INH, RMP and MDR. However, the
GenoType(R) MTBDRsl assay shows limitations in detecting resistance to EMB. The dominance of
single gene mutations associated with the resistance to INH and RMP was observed in the codon 315
of the katG gene and codon 531 of the rpoB gene, respectively.
Publication IV: In this study, the first in-depth analysis of the population structure and transmission
dynamics of M. tuberculosis strains is presented from Northwest Ethiopia. MIRU-VNTR 24-loci
typing and spoligotyping methods were used to identify M. tuberculosis phylogenetic lineages and to
perform cluster analysis. Clusters of strains with identical genotyping patterns were considered as an
indicator for the rate of recent transmission. Of 244 M. tuberculosis isolates, 144 (59.0%) were
classified into nine previously described lineages: 95 (38.9%) were Dehli/CAS, 21(8.6%) Haarlem, 8
(3.3%) Ural, 8 (3.3%) LAM, 5(2.0%) TUR, 3 (1.2%) X-type, 2 (0.8%) S-type, 1 (0.4%) Beijing and 1
(0.4%) Uganda II lineage. Interestingly, 77 (31.6%) of the isolates were grouped into four new
phylogenetic lineages and were named as Ethiopia_3, 32 (13.1%); Ethiopia_1, 19 (7.8%);
Ethiopia_H37Rv like, 17 (7.0%); and Ethiopia_2, 9 (3.7%). The remaining 23 (9.4%) strains could not
be assigned to the known or new lineages. Patients with Haarlem lineages had 22-fold higher odds of
multidrug resistance and 10-fold higher odds for resistance to all first line anti-TB drugs compared
with patients infected with non-Haarlem lineages. Overall, 110 (45.1%) of the isolates were grouped in
clusters, indicating a high rate of recent transmission. Similarly, 8/12 (66.7%) MDR strains were
grouped in clusters, indicating successful transmission of MDR strains within the community. In
conclusion, this study confirms a highly diverse population structure of M. tuberculosis, the presence
of new phylogenetic lineages and a predominance of the Dehli/CAS genotype in Northwest Ethiopia.
The high rate of recent transmission indicates defects of the TB control program in Northwest
Ethiopia. This emphasizes the importance of strengthening laboratory diagnosis of TB, intensified case
finding and treatment of TB patients to interrupt the chain of transmission within the community.
In general, this dissertation is of a paramount importance to the tuberculosis prevention and control
efforts in Ethiopia as it fills the information gaps that are urgently needed by health professionals for
the proper diagnosis and management of tuberculosis patients, and by tuberculosis control program
planners for designing effective prevention and control strategies in the country. Furthermore,
researchers in the field of mycobacteriology can benefit out of the findings of this dissertation.
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